Real Time Genomics, Inc., the genome analytics company, today announced that it had secured a $5mm investment to fund the expansion of commercial operations. The company also disclosed that two leading genome research centers at Stanford University have purchased the company's genome analysis platform. Researchers at the Center for Computational, Evolutionary and Human Genomics and the Stanford Center for Genomics and Personalized Medicine will use the RTG platform as a component in their genome analysis framework to accelerate numerous ongoing population genetics and clinical research projects.

RTG introduced its genomics platform in February to technologists at the AGBT meeting in Marco Island, Florida and to the clinician/research community at the ACMG meeting in March. The announced investment, composed of cash and the conversion of debt, will fund sales, marketing and genomics applications development.

As part of the ongoing relationship with Stanford, RTG, led by Vice President of Genome Science Francisco De La Vega, will collaborate leading scientists in the two centers on areas of common interest.

"This financing marks an evolutionary milestone for the company where we begin to establish a strong commercial presence in the market," said Steve Lombardi, CEO of Real Time Genomics. "This Stanford commitment demonstrates the value of our genomics platform to enable leading-edge basic and translational genetics research."

Real Time Genomics provides analytical platforms for the interpretation of genomes and microbiomes. The platforms are designed for compatibility with raw sequence data generated from leading sequencing platforms, including Illumina, Ion Torrent, and 454. The first version of the genomics platform is the RTG Family Caller for use in family and trio studies. The Family Caller simultaneously analyzes all the genomic data from the related individuals within a patented Bayesian algorithmic framework to accurately identify all classes of variants across the individuals, analyzed in one-tenth the time of competing platforms. Full phasing of the offspring's genomes are reported as the haplotypes of the parents are utilized in the variant calling process. The level of accuracy is sufficient to allow for the identification of de novo variants in the offspring of the families. The platform also provides application"specific callers for case-control studies and the analysis of single genomes, which will be released at a later date.

About Real Time Genomics, Inc.

Real Time Genomics (http://www.realtimegenomics.com) has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomic data. Its competency lies in applying the combination of its patented core technology, deep computational expertise in algorithms to solve problems in next generation genomic analysis, and a team of executives with extensive experience in successful genomics companies. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.